As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted Dr. Robert Niven, for a webinar on “Clinical Trials Endpoints for Severe Asthma” on 08 March, 2017.
A range of clinical trial endpoints are used when assessing therapies for severe asthma. These include lung function, exacerbations, health status, quality of life, bronchial hyperreactivity, airway inflammation and steroid-sparing effects. Different outcomes measures provide different information about the effects of treatment. The use of different clinical trials endpoints for different treatments makes it difficult to compare trials. The relative benefits and drawbacks of clinical trial endpoints are discussed.
Careful selection of endpoint measures is critical. Clinical trial endpoints have largely been selected based on the predicted treatment response for each individual drug. As a result, different outcome measures are assessed for different drugs. Dr. Niven argues that endpoint measures must consider the treatment approach and relevant patient outcomes.
Dr. Robert Niven runs a supra-regional service for severe asthma. He has assessed over 2,000 severe asthma patients, with around 50% of these referrals being for patients on maintenance oral steroids. He is a core member of the UK National Severe Asthma Network, with nearly 1,000 patients entered onto a national database from multiple centres, with Manchester a core contributor.
He has published over 100 peer-reviewed papers and 5 book chapters. Areas of interest have included occupational lung disease, environmental epidemiology and clinical practice in severe asthma. His research has assessed hypertonic saline for bronchiectasis therapy, awareness and diagnosis of dysfunctional breathing patterns, the role of antifungal therapy in severe asthma with fungal sensitisation and trials of bronchial thermoplasty and new biologics.